Celldex Therapeutics, Inc.
Celldex is a biopharmaceutical company researching mast cell biology and developing therapeutic antibodies for severe inflammatory, allergic, autoimmune and other diseases. Its drug candidates include monoclonal and bispecific antibodies designed for mast cell-mediated diseases where available treatments are inadequate. Its main development program is barzolvolimab, a monoclonal antibody targeting KIT, which is being studied in chronic spontaneous and inducible urticaria, prurigo nodularis and atopic dermatitis. Celldex is also developing a bispecific antibody platform for inflammatory diseases; its first candidate, CDX-622, targets TSLP and SCF. Celldex is focused on research and development and has no commercial revenues from sales of its drug candidates. It says it may retain economic rights to therapies or pursue commercial partnerships. Celldex is headquartered in Hampton, NJ.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CLDX in the last 30 days.
See all $CLDX insider activity →Guggenheim reiterated Celldex Therapeutics as its top biotech pick, citing strong Phase III data for barzolvolimab and pipeline opportunities. The firm maintained a Buy rating with a $100 price target, highlighting positive developments in chronic urticaria, atopic dermatitis, and asthma treatments. Celldex plans to submit a Biologics License Application for barzolvolimab in 2027.
Celldex Therapeutics (CLDX) plans to file for barzolvolimab approval by 2027 after Phase 3 results. The company reported 41% of patients maintained complete response 7 months post-treatment in Phase 2. Celldex aims for a premium pricing strategy and is expanding commercial teams. Phase 3 studies for chronic inducible urticaria are enrolling, with atopic dermatitis data expected by year-end. The company's Q3 cash balance is expected to last through 2028.
Canaccord Genuity kept its Buy rating on Celldex Therapeutics and increased its price target to $68 from $60, suggesting a 127.7% upside from the Nov 6 close of $29.87.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning CLDX (Celldex Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.
Recent CLDX coverage spans financial news, earnings and technology.
Analyst upgrade with a high price target may lift the stock.
The news could lift the stock as investors anticipate a regulatory filing and potential commercialization.
Analyst upgrade may lift sentiment and attract buying interest.
Analyst upgrade with higher target may attract buying interest.
Earnings miss and increased loss likely drive the stock lower.
AlphAI scores every news story that mentions CLDX with an AI model for sentiment and relevance, and aggregates insider trades from Celldex Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim reiterated Celldex Therapeutics as its top biotech pick, citing strong Phase III data for barzolvolimab and pipeline opportunities. The firm maintained a Buy rating with a $100 price target, highlighting positive developments in chronic urticaria, atopic dermatitis, and asthma treatments. Celldex plans to submit a Biologics License Application for barzolvolimab in 2027.
Celldex Therapeutics (CLDX) plans to file for barzolvolimab approval by 2027 after Phase 3 results. The company reported 41% of patients maintained complete response 7 months post-treatment in Phase 2. Celldex aims for a premium pricing strategy and is expanding commercial teams. Phase 3 studies for chronic inducible urticaria are enrolling, with atopic dermatitis data expected by year-end. The company's Q3 cash balance is expected to last through 2028.
Canaccord Genuity kept its Buy rating on Celldex Therapeutics and increased its price target to $68 from $60, suggesting a 127.7% upside from the Nov 6 close of $29.87.
Morgan Stanley kept its Overweight rating on Celldex Therapeutics and increased its price target to $61 from $57, suggesting a 104.2% upside from the Nov 6 close of $29.87.
Celldex Therapeutics reported no revenue and a widened net loss of $75.56M for Q3 2026, driven by increased R&D and administrative expenses. The company's barzolvolimab drug showed positive results in Phase 3 studies for CSU, with a BLA submission expected in 2027. R&D expenses rose 7% to $67.4M, primarily for barzolvolimab development.
Celldex Therapeutics, Inc. (CLDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Celldex Reports Third Quarter Financial Results and Provides Corporate Update Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in
HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics with a $64 price target, implying a 98.9% upside from the Oct 1 close of $32.18. The company's pipeline focuses on severe inflammatory and autoimmune diseases, and surveys indicate positive physician sentiment despite safety concerns.
Celldex's barzolvolimab for chronic urticaria showed low anaphylaxis risk, with no black box expected, but stock reacted negatively. Amgen's dazodalibep for Sjögren's showed positive Phase 3 results, targeting a $25B market. Biotech stocks face sentiment challenges despite positive data.
Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.
US PMI data exceeded expectations, with manufacturing and services PMIs at multi-year highs. Wall Street opened lower, with the Dow, S&P 500, and Nasdaq down. IonQ rose 5% after quantum error correction news, while General Mills fell 2% despite earnings beat. Meta's AI agent boosted shares, while biotechs like Viking Therapeutics and Celldex saw mixed movements. FTSE 100 closed flat, with Auto Trader Group leading losses.
